The statins market has the value of around US$ 10.5 Bn in 2019 and is projected to experience stable negative growth over the forecast period from 2020 to 2027.
Statins are a class of drugs also known as HMG-CoA reductase inhibitors, prescribed by doctors for lowering cholesterol levels in the blood. As statins block the enzyme in the liver that is responsible for making cholesterol. The enzyme is called hydroxy-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). Lowering cholesterol levels helps in the prevention of heart attacks and stroke. Statins can prevent and treat atherosclerosis that causes chest pain, heart attacks, strokes, and intermittent claudication. Moreover, studies have also stated that statins can reduce the risk of heart attack, stroke, and even death from heart disease by about 25 to 35 percent and can also reduce the chances of recurrent strokes or heart attacks by about 40%. The amount of cholesterol can be determined by a simple blood test.
A study involving 71,444 people in large 19 clinical trials found that 3.0% of people taking statin died from any cause compared to 3.6% of those taking a placebo. Further analysis has also shown that the average risk of dying from heart disease was 1.7% in the placebo group and 1.2% among those taking statins or can say a benefit of 0.5% for those who are taking statins.
Market Dynamics
The rising prevalence of hypercholesterolemia across the globe especially among the geriatric population is supporting the market value. The increasing number of individuals suffering from other ailments like diabetes, obesity and cardiovascular diseases (CVDs) are accelerating the demand across developed and developing economies. The increasing consumer preference for over-the-counter (OTC) drugs also these OTC variants are usually more affordable are the factors contributing to the market value. The growing adoption of combination therapies that use statin with other cholesterol diminishing compounds including ezetimibe are further bolstering the market value. Additionally, the researchers have also found that statin-ezetimibe combination therapy is capable to achieve nearly normal lipid profiles in familial hypercholesterolemia patients and significantly helps in reducing the risk of CVDs occurrence. Furthermore, improving healthcare infrastructure and growing health consciousness among people is further holding up the market.
On the other hand, the side effects associated with the consumption of statin such as headache, nausea, vomiting, constipation, diarrhea, rash, weakness, and muscle pain are estimated to limit the growth during the forecast period.
Segment Instance
North America accounted for the maximum revenue share in the market
In 2019, North America along with its major economies including US and Canada are contributing to the dominating share of the region. The presence of major players along with the major geriatric population base is supporting the regional market value. The presence of major regulation authorities like United States FDA is further contributing to the regional market value.
Asia Pacific is expected to be the emerging market over the forecast period from 2020 to 2027
The increasing strategic expansion of major players in the developing economies of the region including China and India are bolstering the regional market value. The increasing disposable income is propelling the spending power of people significantly bolstering the demand of drug in the market. The rising awareness about the long term effects of bad cholesterol to overall health is further supporting the regional market value.
Key Market Players
The players profiled in the report include Amgen (US), AstraZeneca (UK), Aurbindo Pharma (India), Biocon (India), Concord Biotech (India), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), and others.
Market Segmentation
Market By Product
Atorvastatin
Fluvastatin (Lescol, Canef, and Vastin)
Lovastatin
Pravastatin (Pravachol)
Rosuvastatin (Crestor)
Simvastatin (Zocor)
Pitavastatin (Livalo)
Market By Type
Synthetic Statins
Natural Statins
Market By Therapeutic Area
Cardiovascular Disorders
Obesity
Inflammatory Disorders
Others
Market By Geography
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Statins
1.1. Definition and Scope
1.1.1. Definition of Statins
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Statins Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Statins Market By Product
1.2.3. Statins Market By Type
1.2.4. Statins Market By Therapeutic Area
1.2.5. Statins Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Statins Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Statins Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Statins Major Manufacturers in 2019
CHAPTER 5. Statins Market By Product
5.1. Introduction
5.2. Statins Revenue By Product
5.2.1. Statins Revenue (US$ Mn) and Forecast, By Product, 2016-2027
5.2.2. Atorvastatin
5.2.2.1. Atorvastatin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Fluvastatin
5.2.3.1. Fluvastatin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Lovastatin
5.2.4.1. Lovastatin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Pravastatin (Pravachol)
5.2.5.1. Pravastatin (Pravachol) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.6. Rosuvastatin (Crestor)
5.2.6.1. Rosuvastatin (Crestor) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.7. Simvastatin (Zocor)
5.2.7.1. Simvastatin (Zocor) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.8. pitavastatin (Livalo)
5.2.8.1. pitavastatin (Livalo) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Statins Market Revenue By Type
6.1. Introduction
6.2. Statins Revenue (US$ Mn) By Type
6.2.1. Statins Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
6.2.2. Synthetic Statins
6.2.2.1. Synthetic Statins Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Natural Statins
6.2.3.1. Natural Statins Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Statins Market By Therapeutic Area
7.1. Introduction
7.2. Statins Revenue (US$ Mn) By Therapeutic Area
7.2.1. Statins Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
7.2.2. Cardiovascular Disorders
7.2.2.1. Cardiovascular Disorders Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Obesity
7.2.3.1. Obesity
7.2.4. Inflammatory Disorders
7.2.4.1. Inflammatory Disorders Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.5. Others
7.2.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Statins Market By Country
8.1. North America Statins Overview
8.2. U.S.
8.2.1. U.S. Statins Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
8.2.2. U.S. Statins Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.2.3. U.S. Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016-2027
8.3. Canada
8.3.1. Canada Statins Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
8.3.2. Canada Statins Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.3.3. Canada Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Statins Market By Country
9.1. Europe Statins Market Overview
9.2. U.K.
9.2.1. U.K. Statins Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.2.2. U.K. Statins Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.2.3. U.K. Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016-2027
9.3. Germany
9.3.1. Germany Statins Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.3.2. Germany Statins Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.3.3. Germany Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016-2027
9.4. France
9.4.1. France Statins Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.4.2. France Statins Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.4.3. France Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016-2027
9.5. Spain
9.5.1. Spain Statins Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.5.2. Spain Statins Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.5.3. Spain Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Statins Market Revenue (US$ Mn) and Forecast By Product, 2016-2027
9.6.2. Rest of Europe Statins Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.6.3. Rest of Europe Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Statins Market By Country
10.1. Asia Pacific Statins Market Overview
10.2. China
10.2.1. China Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.2.2. China Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.2.3. China Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
10.3. Japan
10.3.1. Japan Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.3.2. Japan Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.3.3. Japan Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
10.4. India
10.4.1. India Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.4.2. India Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.4.3. India Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
10.5. Australia
10.5.1. Australia Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.5.2. Australia Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.5.3. Australia Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
10.6. South Korea
10.6.1. South Korea Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.6.2. South Korea Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.6.3. South Korea Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
10.7.2. Rest of Asia-Pacific Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.7.3. Rest of Asia-Pacific Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Statins Market By Country
11.1. Latin America Statins Market Overview
11.2. Brazil
11.2.1. Brazil Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
11.2.2. Brazil Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.2.3. Brazil Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
11.3. Mexico
11.3.1. Mexico Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
11.3.2. Mexico Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.3.3. Mexico Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
11.4.2. Rest of Latin America Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
CHAPTER 12. Middle East & Africa Statins Market By Country
12.1. Middle East & Africa Statins Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
12.2.2. Saudi Arabia Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.2.3. Saudi Arabia Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
12.3. UAE
12.3.1. UAE Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
12.3.2. UAE Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.3.3. UAE Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Statins Market Revenue (US$ Mn) and Forecast By Product, 2016 - 2027
12.4.2. Rest of Middle East & Africa Statins Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.4.3. Rest of Middle East & Africa Statins Market Revenue (US$ Mn) and Forecast By Therapeutic Area, 2016 - 2027
CHAPTER 13. Player Analysis Of Statins
13.1. Statins Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Statins Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. COMPANY PROFILE
14.1. Amgen (US)
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. Amgen (US) 2019 Statins Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.1.6. Manufacturing Plant Footprint Analysis
14.2. AstraZeneca (UK)
14.3. Aurbindo Pharma (India)
14.4. Biocon (India)
14.5. Concord Biotech (India)
14.6. GlaxoSmithKline plc (UK)
14.7. Merck & Co., Inc. (US)
14.8. Pfizer, Inc. (US)
14.9. Others
